Henk Tissing
Chief Tech/Sci/R&D Officer chez ONCOSIL MEDICAL LIMITED
Profil
Henk Tissing is the Director & Global Head-Clinical Affairs at OncoSil Medical Ltd.
He previously worked as the Director-EMEA Clinical Affairs at Sirtex Medical Pty Ltd.
from 2012 to 2018 and as the VP-Clinical Development Interventional Oncology at BTG Ltd.
from 2018 to 2021.
Mr. Tissing received his undergraduate degree from the University of Leiden in 1991.
Postes actifs de Henk Tissing
Sociétés | Poste | Début |
---|---|---|
ONCOSIL MEDICAL LIMITED | Chief Tech/Sci/R&D Officer | - |
Anciens postes connus de Henk Tissing
Sociétés | Poste | Fin |
---|---|---|
BTG | Corporate Officer/Principal | 01/04/2021 |
SIRTEX MEDICAL LIMITED | Corporate Officer/Principal | 01/09/2018 |
Formation de Henk Tissing
University of Leiden | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
ONCOSIL MEDICAL LIMITED | Health Technology |
Entreprise privées | 2 |
---|---|
BTG Ltd.
BTG Ltd. Pharmaceuticals: MajorHealth Technology BTG Ltd. is a global healthcare company, which focuses on interventional medicine that can help physicians to treat patients through minimally invasive procedures. It operates through the following segments: Product, Licensing, and Other. The firm's products include CroFab, DigiFab, Voraxage. The company was founded on December 12, 1991 and is headquartered in Farnham, the United Kingdom. | Health Technology |
Sirtex Medical Pty Ltd.
Sirtex Medical Pty Ltd. Miscellaneous Commercial ServicesCommercial Services Sirtex Medical Ltd. manufactures, and distributes liver cancer treatments. It operates through the following geographical segments: Asia Pacific, Americas, and Europe, Middle East, and Africa. It offers targeted radiation therapy known as SIR Spheres Y-90 resin microspheres. The company was founded in 1997 and is headquartered in St Leonards, Australia. | Commercial Services |